Liver‐targeted gene therapy: Approaches and challenges

Rajagopal N. Aravalli, John D. Belcher, Clifford J. Steer – 30 March 2015 – The liver plays a major role in many inherited and acquired genetic disorders. It is also the site for the treatment of certain inborn errors of metabolism that do not directly cause injury to the liver. The advancement of nucleic acid–based therapies for liver maladies has been severely limited because of the myriad untoward side effects and methodological limitations.

Framingham score, renal dysfunction, and cardiovascular risk in liver transplant patients

Tommaso Di Maira, Angel Rubin, Lorena Puchades, Victoria Aguilera, Carmen Vinaixa, Maria Garcia, Nicola De Maria, Erica Villa, Rafael Lopez‐Andujar, Fernando San Juan, Eva Montalva, Judith Perez, Martin Prieto, Marina Berenguer – 30 March 2015 – Cardiovascular (CV) events represent major impediments to the long‐term survival of liver transplantation (LT) patients. The aim of this study was to assess whether the Framingham risk score (FRS) at transplantation can predict the development of post‐LT cardiovascular events (CVEs). Patients transplanted between 2006 and 2008 were included.

Percutaneous yttrium aluminum garnet–laser lithotripsy of intrahepatic stones and casts after liver transplantation

Nis Hallundbæk Schlesinger, Peter Svenningsen, Susanne Frevert, André Wettergren, Jens Hillingsø – 30 March 2015 – Bile duct stones and casts (BDSs) contribute importantly to morbidity after liver transplantation (LT). The purpose of this study was to estimate the clinical efficacy, safety, and long‐term results of percutaneous transhepatic cholangioscopic lithotripsy (PTCSL) in transplant recipients and to discuss underlying factors affecting the outcome.

Circulating levels of soluble receptor for advanced glycation end products and ligands of the receptor for advanced glycation end products in patients with acute liver failure

Giuseppina Basta, Serena Del Turco, Teresa Navarra, William M. Lee, Acute Liver Failure Study Group – 30 March 2015 – Animal studies suggest that receptor for advanced glycation end products (RAGE)–dependent mechanisms contribute to acetaminophen‐induced liver damage.

Donation after cardiac death liver transplantation: Graft quality evaluation based on pretransplant liver biopsy

Weiliang Xia, Qinghong Ke, Ye Wang, Xiaowen Feng, Haijun Guo, Weilin Wang, Min Zhang, Yan Shen, Jian Wu, Xiao Xu, Sheng Yan, Shusen Zheng – 30 March 2015 – Donation after cardiac death (DCD) liver grafts are associated with inferior clinical outcomes and high discard rates because of poor graft quality. We investigated the predictive value of DCD liver biopsy for the pretransplant graft quality evaluation. DCD liver transplants that took place between October 2010 and April 2014 were included (n = 127).

Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients

Julio A. Gutierrez, Andres F. Carrion, Danny Avalos, Christopher O'Brien, Paul Martin, Kalyan Ram Bhamidimarri, Adam Peyton – 30 March 2015 – Recurrent hepatitis C virus (HCV) infection occurs universally in the allograft in the absence of effective antiviral therapy before liver transplantation (LT). Antiviral therapy with sofosbuvir and simeprevir has proven to be highly effective and well tolerated in the nontransplant setting for treatment of HCV genotype 1 infection; therefore, we sought to evaluate the efficacy and safety of this regimen in LT recipients with recurrent HCV infection.

Subscribe to